SCHEMBL256966

SCHEMBL256966

CC1=NNCC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4562815 0.62
SCHEMBL907941 0.62
Hydrochloric Acid SCHEMBL4412661 0.61
SCHEMBL11332934 0.59
SCHEMBL13979313 0.57
SCHEMBL15030744 0.57
SCHEMBL6858761 0.57
SCHEMBL6565468 0.57
SCHEMBL7703054 0.50
SCHEMBL22746031 0.48

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 612 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-4662905-A REACTION PRODUCT OF COPPER SALT AND AN IMIDAZOLE, PYRAZOLE, TRIAZOLE, OR TETRAZOLE Itaru Todoriki, Director of Agency of Industrial Science and Technology (JP) 1987-05-05 US claimed
WO-2026102082-A1 ALKYLPHENYL SUBSTITUTED COMPOUNDS, COMPOSITIONS AND METHODS OF USE DEEP APPLE THERAPEUTICS, INC. (US) 2026-05-15 WO disclosed
US-20260132119-A1 Alkylphenyl Substituted Compounds, Compositions and Methods of Use DEEP APPLE THERAPEUTICS, INC. (US) 2026-05-14 US disclosed
US-12624043-B2 Compositions useful for treating disorders related to kit BLUEPRINT MEDICINES CORPORATION (US) 2026-05-12 US disclosed
US-20250214984-A1 COMPOUND HAVING KDM5 INHIBITORY ACTIVITY AND PHARMACEUTICAL USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2025-07-03 US disclosed
EP-4146645-B1 3-AZABICYCLO(3.1.0)HEXANE DERIVATIVES HAVING KDM5 INHIBITORY ACTIVITY AND USE THEREOF ONO PHARMACEUTICAL CO (JP) 2025-06-25 EP disclosed
US-12269817-B2 Compound having KDM5 inhibitory activity and pharmaceutical use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2025-04-08 US disclosed
EP-4471027-A1 3-AZABICYCLO(3.1.0)HEXANE DERIVATIVES HAVING KDM5 INHIBITORY ACTIVITY AND USE THEREOF ONO Pharmaceutical Co., Ltd. (JP) 2024-12-04 EP disclosed
US-20240317757-A1 COMPOSITIONS USEFUL FOR TREATING DISORDERS RELATED TO KIT BLUEPRINT MEDICINES CORPORATION (US) 2024-09-26 US disclosed
US-20240238297-A1 USES AND METHODS FOR RECURRENT PRIMARY CNS NEOPLASMS CHIMERIX, INC. 2024-07-18 US disclosed
US-4927452-A 1-carbonyl-2-pyrazoline derivatives having herbicidal activity DUPHAR INTERNATIONAL RESEARCH B.V. (NL) 1990-05-22 US disclosed
EP-0237762-B1 PROCESS FOR THE PREPARATION OF PYRAZOLES BASF Aktiengesellschaft (DE) 1989-06-07 EP disclosed
EP-0269141-A2 1-Carbamoyl-2-pyrazoline derivatives having herbicidal activity DUPHAR INTERNATIONAL RESEARCH B.V (NL) 1988-06-01 EP disclosed
US-4702803-A Preparation of pyrazoles BASF AKTIENGESELLSCHAFT (DE) 1987-10-27 US disclosed
EP-0237762-A1 Process for the preparation of pyrazoles BASF Aktiengesellschaft (DE) 1987-09-23 EP disclosed
EP-0162247-B1 PROCESS FOR THE PREPARATION OF PYRAZOLES BASF Aktiengesellschaft (DE) 1987-08-26 EP disclosed
US-4662905-A REACTION PRODUCT OF COPPER SALT AND AN IMIDAZOLE, PYRAZOLE, TRIAZOLE, OR TETRAZOLE Itaru Todoriki, Director of Agency of Industrial Science and Technology (JP) 1987-05-05 US disclosed
EP-0162247-A1 Process for the preparation of pyrazoles BASF Aktiengesellschaft (DE) 1985-11-27 EP disclosed
US-4424364-A Preparation of pyrazoles BASF AKTIENGESELLSCHAFT (DE) 1984-01-03 US disclosed
EP-0088963-A1 Process for the preparation of pyrazoles by catalytic dehydrogenation of pyrazolines BASF Aktiengesellschaft (DE) 1983-09-21 EP disclosed